Cocktails of 2 mAbs based products are better equipped to deal with variants than single mAb based products which have a tendency of losing their efficacy with rapidly generating variants
The acquisition reflects Johnson & Johnson’s push to strengthen its position in antibody engineering and next-generation oncology modalities
We have the chance to build an IP estate that goes hand in hand with our generic pharmaceutical strength and build proprietary biological platforms
The two companies will establish a joint Center of Excellence (CoE) in Bengaluru
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
The event marks a significant push into South Korea’s rapidly expanding bio-health ecosystem
This event will bring together global stakeholders to explore India’s growing capabilities in pharma and biopharma innovation, research, and manufacturing
Broadens downstream purification portfolio with next-generation Protein A chromatography for scalable manufacturing
The move comes as China rapidly expands its capabilities in the pharmaceutical sector, particularly in licensing and drug development
Iberdomide has the potential to be the first approved CELMoD agent
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
